Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

t December 31, 2009. Of the costs incurred in relation to the OGX-011 development plan, $2.8 million is receivable from Teva as of March 31, 2010. For 2010, we anticipate that we will incur operating expenses of between $30 million and $32 million, an increase from prior guidance which reflects additional manufacturing responsibilities for the Company under the OGX-011 development plan. These additional manufacturing costs are reimbursable from Teva and consequently there will be a corresponding increase in revenue for 2010. We continue to anticipate ending the year with cash, cash equivalents, short-term investments, and amounts receivable of between $29 million and $31 million.

The Company believes that its cash, cash equivalents, short-term investments and amounts receivable will be sufficient to fund its currently planned operations into 2012 and expect that both Phase III prostate cancer trials will be fully accrued by this time. The Company had 6,375,461 shares outstanding as at May 5, 2010.

"So far in 2010 we have advanced towards achieving key objectives for both OGX-011 and OGX-427 and have also added substantial biopharmaceutical experience to our Board of Directors," said Scott Cormack, president and chief executive officer of OncoGenex. "We remain on target to initiate the OGX-011 Phase III trial evaluating OGX-011 with docetaxel retreatment as second-line therapy in castrate-resistant prostate cancer ("CRPC") in the second quarter of 2010, while the Phase III trial evaluating OGX-011 with first-line docetaxel treatment in CRPC, the Phase II trial evaluating OGX-427 as a monotherapy in CRPC, and the Phase III trial evaluating OGX-011 with first-line chemotherapy in non-small cell lung
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Eckert ... Accelerator Mass Spectrometry (AMS) services to the pharmaceutical and ... has joined the company in the position of Director ... years of broad and valuable experience in drug metabolism ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart ... 2014 was a record-breaking year across the board for the ... Smart Data Platform and our Smart Data solutions, our customers ... data which led to record growth for the company in ...
(Date:1/22/2015)... MA (PRWEB) January 22, 2015 zFlo ... is pleased to announce an exciting product from a new ... motion analysis solutions over the past 15 years, with offerings ... Most recently, their 3D IMU system (inertial measurement unit), iSen, ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Four Clinical Stage Product Candidates Adds to Robust ... ... Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) and MacroChem Corporation (OTC ... agreement,providing for Access to acquire MacroChem through the issuance of 2.5,million ...
... (Nasdaq: ALXN ), today announced that the Company ... Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time (ET), ... the second quarter ended June 30, 2008. Alexion,anticipates releasing ... 29, 2008., To participate in this conference call, ...
... Exchange between Physician Community and Leading Biotechnology and ... ... EMD Serono, Inc. announced,today that the company has adopted ... Interactions with Healthcare Professionals.,The revised voluntary Code, which builds on ...
Cached Biology Technology:Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 2Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 3Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 4EMD Serono to Adopt Revised and Strengthened PhRMA Code 2EMD Serono to Adopt Revised and Strengthened PhRMA Code 3EMD Serono to Adopt Revised and Strengthened PhRMA Code 4
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... State University researcher has demonstrated that a variety of environmental ... animal but the next three generations of its offspring. , ... the way genes turn on and offthe epigenetic effect studied ... on in the current issue of the online journal ...
... sizes. Scientists have discovered simple rules that control leaf shape during ... able to accurately emulate leaf growth from a bud. "A ... said lead author Samantha Fox from the John Innes Centre on ... bud, not flat with a pointed tip." By creating a ...
... On March 9, the New York Academy of Sciences ... of Established Regulatory Guidance." This full-day conference will explore ... challenges for follow-on versions of complex drugs. , On ... draft guidelines for implementing the Biologics Price Competition and ...
Cached Biology News:Effects of environmental toxicants reach down through generations 2First model of how buds grow into leaves 2Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: